Tanabe Files Japan Marketing Application for ZYNLONTA in DLBCL
Tanabe Pharma filed a marketing authorization application in Japan for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma.
Related stories
USFDA Approves Sun Pharma’s Supplemental Biologics License Application for Ilumya
M impact | REGULATION | Oct 30, 2026, 02:37 AM UTC
Indonesia Exempts Coal for Off-Grid Plants From Domestic Market Obligation
M impact | REGULATION | Oct 30, 2026, 02:13 AM UTC
Prosecutors Appeal Oh Se-hoon’s Second-Trial Acquittal
A special counsel appealed Oh Se-hoon’s acquittal in a second trial on political-fund law charges.
L impact | REGULATION | Oct 30, 2026, 01:51 AM UTC
France to Deploy Officers for Halloween Protests
The French government announced the deployment amid the risk of violence during Halloween protests.
M impact | REGULATION | Oct 30, 2026, 01:34 AM UTC
Netanyahu Wins Israeli Election, but His Bloc Falls Short of a Majority
The final count shows Netanyahu won the election, but his bloc did not secure a majority.
M impact | REGULATION | Oct 30, 2026, 01:34 AM UTC
China and Switzerland Sign Expanded Free Trade Agreement
Chinese President Xi Jinping and Swiss President Guy Parmelin signed an expanded free trade agreement.
M impact | REGULATION | Oct 30, 2026, 01:09 AM UTC